These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 9923535)
21. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. Prince HM; Rischin D; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Quinn M; Brettell M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P Bone Marrow Transplant; 2000 Nov; 26(9):955-61. PubMed ID: 11100274 [TBL] [Abstract][Full Text] [Related]
22. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034 [TBL] [Abstract][Full Text] [Related]
23. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. Stemmler HJ; Salat C; Lindhofer H; Menzel H; Untch M; Kahlert S; Konecny G; Sauer H; Ledderose G; Heinemann V; Kolb HJ Anticancer Res; 2005; 25(4):3047-54. PubMed ID: 16080564 [TBL] [Abstract][Full Text] [Related]
24. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study. Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213 [TBL] [Abstract][Full Text] [Related]
25. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Brugger W; Fetscher S; Hasse J; Frommhold H; Pressler K; Mertelsmann R; Engelhardt R; Kanz L Semin Oncol; 1998 Feb; 25(1 Suppl 2):42-8. PubMed ID: 9535211 [TBL] [Abstract][Full Text] [Related]
26. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037 [TBL] [Abstract][Full Text] [Related]
27. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study. Toh HC; McAfee SL; Sackstein R; Multani P; Cox BF; Garcia-Carbonero R; Colby C; Spitzer TR Bone Marrow Transplant; 2000 Jan; 25(1):19-24. PubMed ID: 10654009 [TBL] [Abstract][Full Text] [Related]
28. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment. Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541 [TBL] [Abstract][Full Text] [Related]
29. [High dosage therapy and autologous peripheral stem cell transplantation in breast carcinoma]. Kier P; Ruckser R; Buxhofer V; Habertheuer KH; Zelenka P; Tatzreiter G; Hübl G; Kittl E; Hauser A; Sebesta C; Hinterberger W Acta Med Austriaca Suppl; 2000; 52():33-6. PubMed ID: 11261276 [TBL] [Abstract][Full Text] [Related]
30. Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer. De Rosa L; Lalle M; Perillo A; Pierelli L; Salerno MG; Cortesi E; Martelli O; Pandolfi A; Amodeo R; Marzetti L; Mancuso S; Scambia G Anticancer Res; 2001; 21(2B):1367-70. PubMed ID: 11396215 [TBL] [Abstract][Full Text] [Related]
31. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience. Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333 [TBL] [Abstract][Full Text] [Related]
32. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma. Zimmerman TM; Grinblatt DL; Malloy R; Williams SF Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947 [TBL] [Abstract][Full Text] [Related]
33. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837 [TBL] [Abstract][Full Text] [Related]
34. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Koscielniak E; Klingebiel TH; Peters C; Hermann J; Burdach ST; Bender-Götze C; Müller-Weihrich ST; Treuner J Bone Marrow Transplant; 1997 Feb; 19(3):227-31. PubMed ID: 9028550 [TBL] [Abstract][Full Text] [Related]
35. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. Rodenhuis S; Bontenbal M; Beex LV; Wagstaff J; Richel DJ; Nooij MA; Voest EE; Hupperets P; van Tinteren H; Peterse HL; TenVergert EM; de Vries EG; N Engl J Med; 2003 Jul; 349(1):7-16. PubMed ID: 12840087 [TBL] [Abstract][Full Text] [Related]
36. Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer. Lüftner D; Wagner K; Dingeldein G; Haas A; Sezer O; Mergenthaler HG; Wernecke KD; Possinger K Anticancer Res; 1999; 19(4C):3583-90. PubMed ID: 10629656 [TBL] [Abstract][Full Text] [Related]
37. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J; J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969 [TBL] [Abstract][Full Text] [Related]
38. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies. Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; McDermott D; Levine J; Warren D; McCauley M; Wheeler C; Frei E Bone Marrow Transplant; 2001 Sep; 28(5):447-54. PubMed ID: 11593317 [TBL] [Abstract][Full Text] [Related]
39. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. Pedrazzoli P; Martinelli G; Gianni AM; Da Prada GA; Ballestrero A; Rosti G; Frassineti GL; Aieta M; Secondino S; Cinieri S; Fedele R; Bengala C; Bregni M; Grasso D; De Giorgi U; Lanza F; Castagna L; Bruno B; Martino M; Biol Blood Marrow Transplant; 2014 Apr; 20(4):501-6. PubMed ID: 24374214 [TBL] [Abstract][Full Text] [Related]
40. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer. Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]